Middle cerebral artery ischemic stroke and COVID-19: a case report

Guido Bigliardi1 · Ludovico Ciollia · Giada Giovannini1 · Laura Vandelli1 · Maria Luisa Dell’Acqua1 · Giuseppe Maria Borzi1 · Livio Picchetto1 · Francesca Rosafio1 · Riccardo Ricceri1 · Stefano Meletti1,2

Abstract
We present a clinical case of a patient with SARS-CoV-2 infection and respiratory symptoms, complicated with a pro-thrombotic state involving multiple vascular territories and concomitant interleukin-6 increase. This case underlines the possibility to develop a COVID-19-related coagulopathy.

Keywords SARS-CoV-2 · COVID · Coagulopathy · Stroke · IL-6

Introduction
Systemic and neurological complications of SARS-CoV-2 infection are increasingly recognized. Several studies described the typical clinical presentation with fever, cough, and fatigue (Lovato and De Filippis 2020). Most recent publications (Klok et al. 2020) showed how COVID-19 might involve not only the respiratory system but also cause a pro-thrombotic state leading to peripheral veins thrombosis and pulmonary embolism. Here, we report a case of a patient with SARS-CoV-2 infection that developed severe coagulopathy affecting both pulmonary and cerebral vessels.

Clinical case
A 62-year-old patient presented to our emergency room with fever and dyspnea. He was affected by diabetes mellitus, ankylosing spondylitis previously treated with Adalimumab and currently on Secukinumab, and complicated with pulmonary fibrosis.

He was firstly admitted to infectious diseases ward. A nasopharyngeal swap for SARS-CoV-2 resulted positive. Blood exams showed normal white blood cells with low lymphocyte levels and platelet counts, increased levels of D-dimer and lactate dehydrogenase (LDH), and slightly increased C-reactive protein (CRP). Interleukin-6 (IL-6) was also elevated (Table 1).

Therapies with oxygen, hydroxychloroquine, and prophylactic low molecular weight heparin (LMWH) were started. In the following days, the patient respiratory symptoms worsened with increasing need for oxygen therapy. Three days after admission, a marked increase in D-dimer was noted. D-dimer remained elevated in the following days (Fig. 1). Seven days after the admission, he suddenly developed respiratory insufficiency not responding to high flow oxygen administration, requiring ICU admission and mechanical ventilation. Blood exams were repeated; D-dimer was still markedly elevated; in comparison with the exams at admission, increased IL-6 (Fig. 1), severe thrombocytopenia, and only mildly increased prothrombin time and partial thromboplastin time were noted. Of interest, LDH, CRP, and procalcitonin were stable (Table 1). Two days later, at the weaning of anesthesia, the patient presented with left hemiplegia, left hemianopsia, and forced right deviation of gaze. A brain CT showed a wide infarction involving deep and superficial territories of the right middle cerebral artery and a smaller left subcortical infarction. Furthermore, a chest CT-angiography was performed, showing bilateral pulmonary embolism and confirming a severe interstitial involvement of the lungs. Ecocolor doppler of supra-aortic vessels was unremarkable, and cardiac monitoring did not show any arrhythmias. A therapy with anticoagulant dose...
of LMWH was started. Nevertheless, the patient continued to deteriorate and died 2 days later for respiratory failure.

**Discussion**

Arterial and venous thrombotic events are recognized complications of SARS-CoV-2 infection (Klok et al. 2020; Beyrouti et al. 2020). The mechanism leading to SARS-CoV-2-related coagulopathy is extensively reviewed elsewhere (Iba et al. 2020). The immune system appears to play a critical role in the pathogenesis: increased levels of pro-inflammatory cytokines (i.e., IL-6), damage-associated molecular patterns release, and complement activation may trigger platelets aggregation and coagulation cascade (Iba et al. 2020). Lupus anticoagulant and anti-phospholipid antibodies have also been described in COVID-19 patients with thrombotic events (Helms et al. 2020; Zhang et al. 2020), but a causal relation has not been proven. Finally, SARS-CoV-2 might directly target endothelial vascular cells expressing angiotensin converting enzyme 2 receptors, necessary for viral adhesion, leading to endothelial dysfunction and apoptosis with subsequent vasoconstriction, inflammation, and procoagulant state (Varga et al. 2020). Increasing IL-6 plasma concentration during hospitalization has been associated with poor outcome (Zhou et al. 2020); we report a striking increase of IL-6 concomitant with respiratory failure and pulmonary embolisms. Such finding might entail a possible pathogenic role of the cytokine storm in COVID-19-related coagulopathy, although a causative role cannot be proven and more studies are needed. Of note, severe respiratory failure was heralded by a marked D-dimer increase 5 days earlier (Fig. 1). Finally, our patient developed sudden respiratory failure with subsequent need for intubation and sedation preventing an early recognition of

|                      | Day 0          | Day 7          | Normal values   |
|----------------------|----------------|----------------|-----------------|
| WBC                  | $6.22 \times 10^3/mm^2$ | $11.12 \times 10^3/mm^2$ * | $4.0-10.9 \times 10^3/mm^2$ |
| Neutrophils          | $5.43 \times 10^3/mm^2$ | $10.46 \times 10^3/mm^2$ * | $1.8-7.7 \times 10^3/mm^2$ |
| Lymphocytes          | $0.53 \times 10^5/mm^2$ * | $0.40 \times 10^5/mm^2$ * | $1.0-4.5 \times 10^5/mm^2$ |
| Hb                   | 14.3 g/dl *    | 12.9 g/dl *    | 13.5–17.5 g/dl  |
| PTL                  | $117 \times 10^3/mm^2$ * | $68 \times 10^3/mm^2$ * | $150-450 \times 10^3/mm^2$ |
| INR                  | 0.90           | 1.29 *         | 0.84–1.25       |
| D-dimer              | 740 ng/ml *    | 31,910 ng/ml * | 0–500 ng/ml     |
| Fibrinogen           | 491 mg/dl *    | 158 mg/dl *    | 200–400 mg/dl   |
| LDH                  | 1018 U/l *     | 1040 U/l *     | 230–460 U/l     |
| Troponin             | <12 ng/l       | 504 ng/l *     | <34 ng/l        |
| CRP                  | 5.2 mg/dl *    | 4.1 mg/dl *    | 0–0.7 mg/dl     |
| PCT                  | 0.1 ng/ml      | 0.1 ng/ml      | <0.5 ng/ml      |
| IL-6                 | 72.10 pg/ml *  | >2300 pg/ml *  | 0–10 pg/ml      |

WBC: white blood cell, Hb: hemoglobin, PTL: platelets, INR: international normalized ratio, LDH: lactate dehydrogenase, CRP: C-reactive protein, PCT: procalcitonin, IL-6: interleukin-6

**Fig. 1** D-dimer and interleukin-6 (IL-6) variation in time. The line shows an important D-dimer increase 5 days before severe respiratory failure. The two dots show IL-6 level at admission and at the time of severe respiratory failure.
stroke that was diagnosed only 2 days later after weaning of anesthesia. This case underlines the importance of constant neurological monitoring in COVID-19 patients during ICU staying, especially in those with suspected thrombotic events, to detect possible neurological complications. Indeed, stroke is an emerging complication of SARS-CoV-2 infection, and revascularization therapies are available, if the diagnosis is promptly done.

Authors’ contributions Guido Bigliardi, Giada Giovannini, and Stefano Meletti conceived and designed the report. The first draft of the manuscript was written by Guido Bigliardi and Ludovico Ciolli. All authors made substantial contribution to develop the draft, revise the work critically for important intellectual contents. All authors read and approved the final manuscript.

Funding This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

References

Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer S, Goh YY, Humphries F, Jäger HR, Losseff N, Perry R, Shah S, Simister R, Turner D, Chandratheva A, Werring D (2020) Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-323586

Helms J, Tacquard F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clerc-Jehl R, Schenck M, Fagot Gandet F, Faïf-Kremer S, Castelain V, Schneider F, Grunebaum L, Anglès-Cano E, Sattler L, Mertes PM, Meziani F, CRICS TRIGGERSEP Group (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46(6):1089–1098. https://doi.org/10.1007/s00134-020-06062-x

Iba T, Levy JH, Levi M, Thachil J (2020) Coagulopathy in COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14975

Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptijn FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;S0049–3848(20)30120–1. https://doi.org/10.1016/j.thromres.2020.04.013

Lovato A, de Filippis C (2020) clinical presentation of COVID-19: a systematic review focusing on upper airway symptoms. Ear Nose Throat J. 145561320920762:014556132092076. https://doi.org/10.1177/0145561320920762

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel A, Mehr M, Schuepbach R, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet. 395(10234):1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C, Zhao J, Sun X, Tian R, Wu W, Wu D, Ma J, Chen Y, Zhang D, Xie J, Yan X, Zhou X, Liu Z, Wang J, Du B, Qin Y, Gao P, Qin X, Xu Y, Zhang W, Li T, Zhang F, Zhao Y, Li Y, Zhang F (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38. https://doi.org/10.1056/NEJMra2007575

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.